9VQ Stock Overview
Develops and commercialize oxygen related medical device products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Belluscura plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.11 |
| 52 Week High | UK£0.28 |
| 52 Week Low | UK£0.08 |
| Beta | 1.15 |
| 11 Month Change | -13.95% |
| 3 Month Change | -2.63% |
| 1 Year Change | -59.19% |
| 33 Year Change | -90.00% |
| 5 Year Change | n/a |
| Change since IPO | -81.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VQ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.1% | -2.2% | -0.2% |
| 1Y | -59.2% | -6.1% | 7.8% |
Return vs Industry: 9VQ underperformed the German Medical Equipment industry which returned -5.6% over the past year.
Return vs Market: 9VQ underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 9VQ volatility | |
|---|---|
| 9VQ Average Weekly Movement | 13.9% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9VQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9VQ's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 35 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products in the United States. The company offers X-PLOR and DISCOV-R, a modular portable oxygen concentrator; and related accessories. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
| 9VQ fundamental statistics | |
|---|---|
| Market cap | €20.15m |
| Earnings (TTM) | -€17.56m |
| Revenue (TTM) | €1.70m |
11.8x
P/S Ratio-1.1x
P/E RatioIs 9VQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VQ income statement (TTM) | |
|---|---|
| Revenue | US$1.80m |
| Cost of Revenue | US$5.37m |
| Gross Profit | -US$3.57m |
| Other Expenses | US$15.04m |
| Earnings | -US$18.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -197.53% |
| Net Profit Margin | -1,030.73% |
| Debt/Equity Ratio | 0% |
How did 9VQ perform over the long term?
See historical performance and comparison